Glucocorticoid response elements and 11β-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression

被引:72
作者
Liu, Yong [1 ]
Mladinov, Domagoj [1 ]
Pietrusz, Jennifer L. [1 ]
Usa, Kristie [1 ]
Liang, Mingyu [1 ]
机构
[1] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA
基金
美国国家卫生研究院;
关键词
HUMAN ESSENTIAL-HYPERTENSION; SALT-SENSITIVE HYPERTENSION; OXIDATIVE STRESS; GENE-EXPRESSION; TYPE-2; RECEPTOR; CELLS; MECHANISMS; RATS; LOCALIZATION;
D O I
10.1093/cvr/cvn231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertensive and other effects of excess glucocorticoids might be in part mediated by the suppression of endothelial nitric oxide synthase (eNOS) expression. We studied the transcriptional and biochemical mechanisms that mediate or modulate the suppression of eNOS expression by glucocorticoids. We found that a mere three-fold increase in the concentration of the natural glucocorticoid cortisol (from 30 to 100 nmol/L) significantly decreased the expression level of eNOS in human endothelial cells. Deletion analysis of the eNOS promoter indicated that the segment within -119 bp upstream from the transcription start site was significantly involved in the effect of cortisol. Site-directed mutagenesis and chromatin immunoprecipitation analyses demonstrated the presence of a suppressive glucocorticoid response element (GRE) at -111 to -105 bp. 11 beta-hydroxysteroid dehydrogenases (11 beta-HSD) catalyse the interconversion of active and inactive glucocorticoids. The suppression of 11 beta-HSD2 using small interfering RNA markedly exacerbated the inhibition of eNOS by cortisol. The suppression of 11 beta-HSD1 abolished the inhibition of eNOS expression by cortisol. We identified the first GRE in the eNOS promoter region and demonstrated that endogenous 11 beta-HSD1 and 11 beta-HSD2 play significant and distinct roles in modulating the effect of glucocorticoids on eNOS expression.
引用
收藏
页码:140 / 147
页数:8
相关论文
共 41 条
[1]   CA-repeat polymorphism in intron 1 of HSD11B2 - Effects on gene expression and salt sensitivity [J].
Agarwal, AK ;
Giacchetti, G ;
Lavery, G ;
Nikkila, H ;
Palermo, M ;
Ricketts, M ;
McTernan, C ;
Bianchi, G ;
Manunta, P ;
Strazzullo, P ;
Mantero, F ;
White, PC ;
Stewart, PM .
HYPERTENSION, 2000, 36 (02) :187-194
[2]   Impaired 11-β hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension [J].
Bocchi, B ;
Kenouch, S ;
Lamarre-Cliche, M ;
Muffat-Joly, M ;
Capron, MH ;
Fiet, J ;
Morineau, G ;
Azizi, M ;
Bonvalet, JP ;
Farman, N .
HYPERTENSION, 2004, 43 (04) :803-808
[3]   Structural analysis and evaluation of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) gene in human essential hypertension [J].
Brand, E ;
Kato, N ;
Chatelain, N ;
Krozowski, ZS ;
Jeunemaitre, X ;
Corvol, P ;
Plouin, PF ;
Cambien, F ;
Pascoe, L ;
Soubrier, F .
JOURNAL OF HYPERTENSION, 1998, 16 (11) :1627-1633
[4]   Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells [J].
Brem, AS ;
Bina, RB ;
King, TC ;
Morris, DJ .
HYPERTENSION, 1998, 31 (01) :459-462
[5]   11β-hydroxysteroid dehydrogenase type 2 in mouse aorta -: Localization and influence on response to glucocorticoids [J].
Christy, C ;
Hadoke, PWF ;
Paterson, JM ;
Mullins, JJ ;
Seckl, JR ;
Walker, BR .
HYPERTENSION, 2003, 42 (04) :580-587
[6]  
Dostert A, 2004, CURR PHARM DESIGN, V10, P2807
[7]   11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action [J].
Draper, N ;
Stewart, PM .
JOURNAL OF ENDOCRINOLOGY, 2005, 186 (02) :251-271
[8]   LOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR [J].
EDWARDS, CRW ;
BURT, D ;
MCINTYRE, MA ;
DEKLOET, ER ;
STEWART, PM ;
BRETT, L ;
SUTANTO, WS ;
MONDER, C .
LANCET, 1988, 2 (8618) :986-989
[9]   Interaction between an 11βHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians [J].
Franks, PW ;
Knowler, WC ;
Nair, S ;
Koska, J ;
Lee, YH ;
Lindsay, RS ;
Walker, BR ;
Looker, HC ;
Permana, PA ;
Tataranni, PA ;
Hanson, RL .
HYPERTENSION, 2004, 44 (05) :681-688
[10]   MINERALOCORTICOID ACTION - TARGET TISSUE-SPECIFICITY IS ENZYME, NOT RECEPTOR, MEDIATED [J].
FUNDER, JW ;
PEARCE, PT ;
SMITH, R ;
SMITH, AI .
SCIENCE, 1988, 242 (4878) :583-585